<DOC>
	<DOCNO>NCT00639834</DOCNO>
	<brief_summary>The purpose study determine MDX-1342 give combination Methotrexate safe treatment patient active rheumatoid arthritis . In addition , change severity patient ' arthritis also analyse .</brief_summary>
	<brief_title>Study Safety MDX-1342 Combination With Methotrexate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must meet ACR criterion diagnosis rheumatoid arthritis ( RA ) Must active RA Must treat Methotrexate ( MTX ) ( 10 25 mg weekly ) least 3 month receive stable dose least 28 day prior anticipate study drug administration date . All DMARDs biologics must discontinue least 28 day prior study drug administration : 1 ) Leflunomide , must discontinue least 60 day study drug administration , 2 ) infliximab , adalimumab , abatacept must discontinue least 56 day prior study drug administration Both Rheumatoid factor antiCCP negative Prior treatment Bcell deplete therapy Any mAb Igbased fusion proteins 56 day less prior Visit History current inflammatory joint disease RA Neuropathies neurovasculopathies might interfere pain evaluation Complications RA disease Any autoimmune disease RA Acute chronic infection Clinically significant disease require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>rheumatoid</keyword>
	<keyword>arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>joint inflammation</keyword>
	<keyword>autoimmune</keyword>
	<keyword>Medarex</keyword>
	<keyword>Rheumatology</keyword>
</DOC>